Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 5/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.44 |
| ▸ | FABP4 | P15090 | 6/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19643503 | 0.90 | MAP4K4 (0.48) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 | |
| SCHEMBL10467284 | 0.86 | FABP4 (0.49) | MAP4K4PDE5AFABP4 | |
| SCHEMBL14916469 | 0.85 | SIRT1 (0.49) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 | |
| SCHEMBL15129165 | 0.85 | SIRT1 (0.49) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 | |
| SCHEMBL15129328 | 0.85 | SIRT1 (0.49) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 | |
| SCHEMBL9364527 | 0.84 | ESR1 (0.49) | MAP4K4PDE5AFABP4 | |
| SCHEMBL23552445 | 0.81 | P2RX7 (0.52) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 | |
| SCHEMBL19285262 | 0.81 | P2RX7 (0.46) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 | |
| SCHEMBL29552779 | 0.81 | P2RX7 (0.46) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 | |
| SCHEMBL23670494 | 0.81 | P2RX7 (0.46) | MAP4K4PDE5AP2RX7SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | ABBVIE S.Á.R.L. (LU) | 2018-11-06 | — | — | US | disclosed |
| WO-2017187321-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | AbbVie S.à.r.l. (LU) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | MAP4K4 2938/4885PDE5A 4155/4885P2RX7 4592/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | MAP4K4 2938/4885PDE5A 4155/4885P2RX7 4592/4885 |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | MAP4K4 31/4885PDE5A 1935/4885P2RX7 2501/4885 |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | MAP4K4 4444/4885PDE5A 530/4885P2RX7 979/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | MAP4K4 31/4885PDE5A 1935/4885P2RX7 2501/4885 |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | CFTR, CHRM2, CHRM1 | MAP4K4 4444/4885PDE5A 530/4885P2RX7 979/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | MAP4K4 2938/4885PDE5A 4155/4885P2RX7 4592/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | MAP4K4 2938/4885PDE5A 4155/4885P2RX7 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.